yondelis 1mg polvo para concentrado en solucion por infusion i.v.
asofarma s.a. - trabectedina - trabectedina....1mg
trabectedin sun 0,25 mg pulver für ein konzentrat zur herstellung einer infusionslösung
trabectedin sun 1 mg pulver für ein konzentrat zur herstellung einer infusionslösung
yondelis 0,25 mg vial pols
yondelis 1 mg vial pols
trabectedine teva 0.25 mg inj. sol. (pwdr., conc.) i.v. vial
teva b.v. - trabectedin 0,25 mg - powder for concentrate for solution for infusion - 0,25 mg - trabectedin 0.25 mg - trabectedin
trabectedine teva 1 mg inj. sol. (pwdr., conc.) i.v. vial
teva b.v. - trabectedin 1 mg - powder for concentrate for solution for infusion - 1 mg - trabectedin 1 mg - trabectedin
yondelis- trabectedin injection, powder, lyophilized, for solution
janssen products, lp - trabectedin (unii: id0yzq2tcp) (trabectedin - unii:id0yzq2tcp) - trabectedin 0.05 mg in 1 ml - yondelis® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see clinical studies (14)] . yondelis is contraindicated in patients with known severe hypersensitivity, including anaphylaxis, to trabectedin. risk summary based on its mechanism of action, trabectedin can cause fetal harm when administered during pregnancy [see clinical pharmacology (12.1)] . there are no available data with the use of yondelis during pregnancy. animal reproductive and developmental studies at relevant doses have not been conducted with trabectedin; however, placental transfer of trabectedin was demonstrated in pregnant rats. advise pregnant woman of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated population are unknown; however, the background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recog
yondelis 1 mg
megapharm ltd - trabectedin - powder for concentrate for solution for injection - trabectedin 1 mg/vial - trabectedin - trabectedin - yondelis is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
trabectedine sun 0.25 mg inj. sol. (pwdr., conc.) i.v. vial
sun pharmaceutical industries europe b.v. - trabectedin 0,25 mg - powder for concentrate for solution for infusion - trabectedin